Zerodha’s Nithin Kamath says India’s response to affordable weight-loss drugs is ‘weird’. Here’s why

Zerodha’s Nithin Kamath Criticizes India’s Slow Adoption of Affordable Weight-Loss Drugs

Theindiapostdaily.com – Zerodha s Nithin Kamath has highlighted a puzzling trend in India’s healthcare landscape, where the response to affordable weight-loss drugs appears inconsistent despite growing public health concerns. As obesity rates climb and the demand for effective weight management solutions intensifies, the low uptake of cost-effective GLP-1 medications raises questions about patient behavior, prescribing practices, and the pharmaceutical industry’s strategy. Kamath’s observations, shared in a recent commentary, point to a paradox: drugs that could revolutionize obesity treatment are not seeing the adoption expected in a country where accessibility and affordability are often prioritized.

Why the Delay in Embracing GLP-1 Drugs?

The market dynamics around GLP-1 drugs, such as semaglutide, have shifted significantly since their patent expiration. Initially, these medications were expected to see rapid growth in India due to their relatively low cost compared to branded alternatives. However, the reality has been slower, with some manufacturers scaling back their sales projections. Kamath’s remarks come after *The Economic Times* reported that Indian drugmakers had initially forecast substantial sales but later revised their expectations, citing a lack of consumer traction. This hesitation is particularly striking given the global success of such drugs in managing weight and related health conditions.

India is a weird market. With obesity rates shooting up, I’d have bet on the sales of generic GLP-1s exploding once their patents expired. They now cost about ₹1,000–2,500 a month, and there’s growing evidence pointing to benefits well beyond weight loss, including cardiovascular, metabolic, and liver health.

Even as GLP-1 drugs become more affordable, their adoption remains subdued. Kamath argues that the real challenge lies in ensuring long-term adherence. Unlike gym memberships or diet programs, these medications require consistent weekly injections. Patients who discontinue use often regain weight, making the commitment to regular administration a critical factor in their success. Despite this, the drugs are not gaining the momentum they deserve, according to Kamath’s analysis.

Pricing vs. Retention: The Sticky Issue

While affordability is a key driver in healthcare decision-making, it is not the only factor influencing drug adoption. Kamath emphasizes that the true hurdle for GLP-1 drugs in India is retention—keeping patients on treatment long enough to see meaningful results. Although these medications are significantly cheaper than their branded counterparts, the cost of weekly injections is still a barrier for some. Patients often face logistical challenges, such as visiting a healthcare facility for administration, which can deter consistent use. This issue is compounded by the fact that weight loss is not immediate, requiring sustained effort and patience.

Additionally, the psychological aspect of self-injection plays a role. Kamath notes that the act of injecting oneself daily can create friction, leading to inertia in starting treatment. This is a key insight, as it underscores the importance of convenience in patient compliance. If patients perceive the process as cumbersome, they are less likely to stick with it, regardless of cost. The transition to oral formulations may address this challenge, but for now, the injection method is limiting progress.

Prescribing Practices and the Role of Doctors

The slow adoption of GLP-1 drugs is also linked to prescribing habits among Indian physicians. Kamath suggests that doctors may be cautious in recommending these medications, perhaps due to unfamiliarity with their mechanisms or concerns about long-term effects. This hesitancy could be a significant factor in the drugs’ limited reach, as healthcare providers often influence patient choices. Moreover, the lack of clear guidelines or awareness campaigns may contribute to a conservative approach in treatment recommendations.

Another challenge is the competition from traditional weight loss methods. While GLP-1 drugs offer a scientific and effective alternative to diets and exercise, they are not seen as a panacea. Many patients opt for lifestyle changes first, which can delay the use of pharmacological interventions. Kamath’s critique highlights the need for a more proactive approach from healthcare professionals to encourage the use of these drugs as part of a comprehensive weight management strategy.

As the pharmaceutical industry continues to navigate this complex landscape, the potential for change remains high. With the development of oral GLP-1 alternatives, the barrier to adoption could be further reduced. This shift may not only improve patient compliance but also open new avenues for market growth. Kamath’s insights serve as a reminder that affordability alone is not enough—strategies to simplify usage and educate both patients and providers are essential for widespread acceptance.